510(k) Report

510(k) · Cleared

Cleared

Mammaprint

K101454510(k) TraditionalCleared Jan 28, 2011248-day reviewClass II21 CFR 866.6040

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Agendia · NYI Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer

Cleared on Jan 28, 2011 as substantially equivalent to K081092 (Agendia, 2009) after a 248-day review. Its family tree reaches back 4 generations to 2007. 3 later devices descend from it.

Decided
Jan 28, 2011
Review
248 days
Class
Class II
Product code
NYI
Recalls
None
Predicates
1

Its longest line of descent runs back 4 generations to DEN070009 (2007). 3 later devices descend from it, 1 citing it directly.

Descendants, by generation 1 generation forward: 1 descendant2 generations forward: 1 descendant3 generations forward: 1 descendant K081092 · Modification to Mammaprint · Agendia · 2009 · recalledK080252 · Modification to Mammaprint · Agendia BV · 2008 · recalledK070675 · Mammaprint · Agendia BV · 2007 · recalledDEN070009 · Mammaprint · Agendia BV · 20070
  1. Root · 4 generations backDEN070009 MammaprintAgendia BV · 2007
  2. 3 generations backK070675 MammaprintAgendia BV · 2007 · Recalled
  3. 2 generations backK080252 Modification to MammaprintAgendia BV · 2008 · Recalled
  4. 1 generation backK081092 Modification to MammaprintAgendia · 2009 · Recalled
  5. This deviceK101454 MammaprintAgendia · 2011
  6. Descendant · cites it directly · 2 of its ownK141142 Mammaprint FfpeAgendia · 2015
  7. Descendant · 2 generations on · 1 of its ownK201902 MammaPrintAgendia, Inc. · 2020
  8. Descendant · 3 generations on · 0 of its ownK210973 MammaPrint FFPE NGS KitAgendia, Inc. · 2022

Most influential descendants

Showing 3 of 3 · See all
  • K141142Mammaprint FfpeAgendia · 2015 · cites it directly2descendants
  • K201902MammaPrintAgendia, Inc. · 2020 · 2 generations on1descendant
  • K210973MammaPrint FFPE NGS KitAgendia, Inc. · 2022 · 3 generations on0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−4DEN070009MammaprintAgendia BV2007—
−3K070675MammaprintAgendia BV20071
−2K080252Modification to MammaprintAgendia BV20081
−1K081092Modification to MammaprintAgendia20091
0 (this device)K101454MammaprintAgendia2011—
+1K141142Mammaprint FfpeAgendia2015—
+2K201902MammaPrintAgendia, Inc.2020—
+3K210973MammaPrint FFPE NGS KitAgendia, Inc.2022—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
201510
202010
202210
FIG. 1 — Lineage of K101454, 2007–2022Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in NYI? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new NYI device

  1. #1 K210973 MammaPrint FFPE NGS Kitscore 5.8 · 7 generations · no Class I recall
  2. #2 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K081092Modification to Mammaprint
Summary page 1
…Name Multivariate device for cancer prognosis 8. Classification Class 11,regulated under 21 CFR 866.6040, product code NYI 9. Predicate Device Agendia By's MammaPrint (k081092) Agendia BV-Amnsterdamn 2010- 1001 Additional Scanner…
Agendia20091
†K080252Modification to MammaprintAgendia BV20081

Also cleared against K081092: 1 other device →

What descends from it? (3)

1 later device cites it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K141142Mammaprint FfpeAgendia20152

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 4 years and passes through 2 companies; a new generation was cleared every 1.1 years on median.
  • 3 of the 4 ancestors have a recall of any class.
  • Of its descendants, K141142 (Agendia, 2015) has gone furthest, with 2 descendants of its own.
  • 1 other device also cites its predicate K081092.

How does its category compare?

All NYI devices

NYI Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer: FDA decisions, review times, recalls and adverse event reports over 20 years. 2011, this device’s year, is highlighted.

FDA decisions per year · NYI

1in 2022

2007: 22008: 12009: 12011: 12013: 12014: 12015: 12020: 12022: 1
2007high 2 (2007) · low 0 (2010)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · NYI

Too few NYI 510(k)s in any year since 2007 to give a median.

Recalls per year · NYI

1in 2010

2010: 1
2007high 1 (2010) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · NYI

1in 2023

2023: 1
2007high 1 (2023) · low 0 (2007)2025

MAUDE reports naming product code NYI, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20072—00
20081—00
20091—00
20100—10
20111—00
20120—00
20131—00
20141—00
20151—00
20160—00
20170—00
20180—00
20190—00
20201—00
20210—00
20221—00
20230—01
20240—00
20250—00
20260—0—

What is it indicated for?

MammaPrint is aqualitative in vitro diagnostic test service, performed in a central laboratory, using the gene expression profile of fresh breast cancer tissue samples to assess a patients' risk for distant metastasis (up to 10 years for patients less than 61 years old, up to 5 years for patients' 61 years).

The test is performed for breast cancer patients with Stage I or Stage 11disease, with a tumor size of 5 5.0 cm and lymph node negative. The MammaPrint result is indicated for use by physicians as a prognostic marker only, along with a other clinicopathological factors.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K101454: Mammaprint.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K101454

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026